Structural basis of histone H2A lysine 119 deubiquitination by Polycomb Repressive Deubiquitinase BAP1/ASXL1.
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
23 Feb 2023
23 Feb 2023
Historique:
entrez:
3
3
2023
pubmed:
4
3
2023
medline:
4
3
2023
Statut:
epublish
Résumé
The maintenance of gene expression patterns during metazoan development is achieved by the actions of Polycomb group (PcG) complexes. An essential modification marking silenced genes is monoubiquitination of histone H2A lysine 119 (H2AK119Ub) deposited by the E3 ubiquitin ligase activity of the non-canonical Polycomb Repressive Complex 1. The Polycomb Repressive Deubiquitinase (PR-DUB) complex cleaves monoubiquitin from histone H2A lysine 119 (H2AK119Ub) to restrict focal H2AK119Ub at Polycomb target sites and to protect active genes from aberrant silencing. BAP1 and ASXL1, subunits that form active PR-DUB, are among the most frequently mutated epigenetic factors in human cancers, underscoring their biological importance. How PR-DUB achieves specificity for H2AK119Ub to regulate Polycomb silencing is unknown, and the mechanisms of most of the mutations in BAP1 and ASXL1 found in cancer have not been established. Here we determine a cryo-EM structure of human BAP1 bound to the ASXL1 DEUBAD domain in complex with a H2AK119Ub nucleosome. Our structural, biochemical, and cellular data reveal the molecular interactions of BAP1 and ASXL1 with histones and DNA that are critical for remodeling the nucleosome and thus establishing specificity for H2AK119Ub. These results further provide a molecular explanation for how >50 mutations in BAP1 and ASXL1 found in cancer can dysregulate H2AK119Ub deubiquitination, providing new insight into understanding cancer etiology. We reveal the molecular mechanism of nucleosomal H2AK119Ub deubiquitination by human BAP1/ASXL1.
Identifiants
pubmed: 36865140
doi: 10.1101/2023.02.23.529554
pmc: PMC9980132
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : R01 CA266978
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM115882
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM138181
Pays : United States
Organisme : NIGMS NIH HHS
ID : R44 GM119893
Pays : United States
Commentaires et corrections
Type : UpdateIn
Références
Sci Adv. 2019 Sep 18;5(9):eaax1738
pubmed: 31555735
Genes Dev. 2021 May 1;35(9-10):749-770
pubmed: 33888563
Biochem Soc Trans. 2021 Jun 30;49(3):1041-1054
pubmed: 34156443
Cancer Res. 2018 Mar 1;78(5):1200-1213
pubmed: 29284740
Nat Rev Genet. 2007 Jan;8(1):9-22
pubmed: 17173055
Protein Sci. 2021 Jan;30(1):70-82
pubmed: 32881101
Nat Methods. 2017 Apr;14(4):331-332
pubmed: 28250466
Cell Death Discov. 2021 Jan 22;7(1):20
pubmed: 33483476
Nat Cancer. 2021 May;2(5):515-526
pubmed: 35122023
Science. 2006 Feb 10;311(5762):856-61
pubmed: 16469929
Protein Sci. 2021 Jan;30(1):136-150
pubmed: 33030237
Nat Methods. 2019 Aug;16(8):771-777
pubmed: 31308549
Methods Enzymol. 2010;481:109-26
pubmed: 20887855
Cell. 2019 Mar 7;176(6):1490-1501.e12
pubmed: 30765112
DNA Repair (Amst). 2015 Dec;36:36-42
pubmed: 26422137
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Nucleic Acids Res. 2020 Sep 25;48(17):9415-9432
pubmed: 32658293
J Struct Biol. 2016 Jan;193(1):1-12
pubmed: 26592709
Nat Methods. 2017 Mar;14(3):290-296
pubmed: 28165473
Bioinformatics. 2012 Aug 1;28(15):1953-6
pubmed: 22645167
Cancer Res. 2014 Aug 15;74(16):4282-94
pubmed: 24894717
J Mol Biol. 1987 Apr 5;194(3):531-44
pubmed: 3041007
Annu Rev Biochem. 2012;81:203-29
pubmed: 22524316
Nat Struct Mol Biol. 2022 May;29(5):493-501
pubmed: 35581345
Science. 2021 Jan 22;371(6527):
pubmed: 33479126
Methods Enzymol. 2004;375:23-44
pubmed: 14870657
Cancer Discov. 2020 Aug;10(8):1103-1120
pubmed: 32690542
Elife. 2020 Jan 10;9:
pubmed: 31922488
Mol Cell. 2015 Mar 5;57(5):887-900
pubmed: 25702870
Science. 2011 Nov 18;334(6058):977-82
pubmed: 22096199
Nature. 2016 Aug 4;536(7614):100-3
pubmed: 27462807
Stem Cell Reports. 2019 May 14;12(5):861-868
pubmed: 31006630
Nat Methods. 2013 Jun;10(6):584-90
pubmed: 23644547
Nat Methods. 2021 Mar;18(3):303-308
pubmed: 33589837
Transl Lung Cancer Res. 2017 Jun;6(3):270-278
pubmed: 28713672
Mod Pathol. 2015 Aug;28(8):1043-57
pubmed: 26022455
Nat Commun. 2016 Jan 07;7:10292
pubmed: 26739236
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
Nature. 2014 Oct 30;514(7524):591-6
pubmed: 25355358
Transl Vis Sci Technol. 2019 May 06;8(3):11
pubmed: 31110912
Nature. 2010 Sep 30;467(7315):562-6
pubmed: 20739938
Science. 2021 Jan 22;371(6527):
pubmed: 33479123
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
Mol Cell. 2021 Sep 2;81(17):3526-3541.e8
pubmed: 34186021
Elife. 2018 Nov 09;7:
pubmed: 30412051
Nat Commun. 2019 Jan 21;10(1):348
pubmed: 30664650
J Mol Biol. 2002 Jun 21;319(5):1097-113
pubmed: 12079350
Structure. 2019 Mar 5;27(3):528-536.e4
pubmed: 30639226
J Exp Med. 2013 Nov 18;210(12):2641-59
pubmed: 24218140
Blood. 2018 Jan 18;131(3):328-341
pubmed: 29113963
Nat Med. 2018 Jun;24(6):758-769
pubmed: 29785026
Curr Opin Struct Biol. 2016 Apr;37:54-61
pubmed: 26764865
Nat Commun. 2018 Sep 26;9(1):3932
pubmed: 30258054
Methods. 2014 Dec;70(2-3):134-8
pubmed: 25063569
PLoS One. 2019 Feb 4;14(2):e0211507
pubmed: 30716094
Mol Cell. 2019 Jun 6;74(5):1010-1019.e6
pubmed: 30981630
Mol Cell. 2021 Jan 7;81(1):166-182.e6
pubmed: 33238161
Org Biomol Chem. 2016 Jan 21;14(3):835-9
pubmed: 26615908
Nat Commun. 2021 Jan 29;12(1):714
pubmed: 33514705
Nature. 2010 May 13;465(7295):243-7
pubmed: 20436459